| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3992056 | Journal of Thoracic Oncology | 2008 | 9 Pages |
Abstract
Addition of standard-dose erlotinib to chemoradiotherapy is feasible without evident increase in toxicities. However, the survival data are disappointing in this unselected patient population and does not support further investigation of this approach.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nicholas W. MD, Ann M. MD, Daniel J. MD, Eric MD, Philip C. MD, Mark MD, Shang PhD, Janet E. MD, Livia RN, Tatyana PhD, Olufunmilayo I. MD, Ravi MD, PhD, Everett E. MD,